Literature DB >> 2527816

Proliferation of resting B cells is modulated by CR2 and CR1.

J D Fingeroth1, M E Heath, D M Ambrosino.   

Abstract

Absence of the third component of complement, C3, is associated with impaired ability to synthesize antibody, particularly in the presence of limiting antigen [1-9]. The mature B lymphocyte bearing the surface immunoglobulin receptor transduces signals for proliferation and differentiation upon binding of specific antigen. This mature B cell also bears two related membrane proteins, CR2 (the C3d/Epstein-Barr virus receptor) (CD35) [15], which can mediate the binding of ligands to which appropriate cleavage fragments of C3 have become attached [16]. It has been suggested that these receptors play a direct role(s) in B cell activation [17-25]. In light of previous in vivo observations we decided to assess the function of CR2 and CR1 in relation to B cell activation through the membrane IgM receptor. Highly purified splenic B cells were prepared. No contaminating T cells or macrophages were detected by flow cytometric analysis and no proliferative activity was present upon PHA or ConA stimulation of the purified cells. The B cells were separated into low (activated), medium (preactivated) and high density (resting) fractions by Percoll gradient density centrifugation [26]. The responses of the B cell subpopulations to various concentrations of anti mu (DA4.4 monoclonal antibody) [27] were examined for proliferation at 72 h and for IgM/IgG production at 7 days. Low density B cells were maximally stimulated and no concentration of anti-mu was effective in enhancing their responses. High density B cells proliferated to anti-mu in a concentration dependent manner. When substimulatory concentrations of anti-mu were employed, concomitant crosslinking of CR2 (with either of 2 distinct monoclonal antibodies HB-5 [28] or OKB7 [17]) resulted in a 45% enhancement of B cell proliferation above that observed by crosslinking of SIgM alone. In these studies, total IgM and IgG did not increase in the absence of T cells or T cell factors, indicating that terminal differentiation did not occur. In contrast, when a monoclonal antibody to CR1(44D) [29] was employed in an identical experiment, B cell proliferation was completely inhibited. Antibodies to CR2 or CR1 either alone or in crosslinked form did not enhance B cell proliferation. Immune complexes may crosslink the B cell surface in a manner analogous to our model when the immunoglobulin receptor and CR2 are simultaneously engaged. This activation signal may be particularly important in eliciting antibody responses when the quantity of specific antigen or the affinity for antigen is low. The marked inhibition of proliferation induced by CR1 suggests an alternate role for this receptor in modulation of B cell responses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527816     DOI: 10.1016/0165-2478(89)90022-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

Review 2.  Adherence and receptor relationships of Candida albicans.

Authors:  R A Calderone; P C Braun
Journal:  Microbiol Rev       Date:  1991-03

Review 3.  Cross-linking the Leu-8 lymph node homing receptor on B cells inhibits immunoglobulin synthesis.

Authors:  Y Murakawa; W Strober; S P James
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

4.  An association between homozygous C3 deficiency and low levels of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  M A Hazlewood; D S Kumararatne; A D Webster; M Goodall; P Bird; M Daha
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

5.  Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.

Authors:  A W Griffioen; G T Rijkers; P Janssens-Korpela; B J Zegers
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

6.  Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).

Authors:  H V Marquart; A Svendsen; J M Rasmussen; C H Nielsen; P Junker; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  Relative Impact of Complement Receptors CD21/35 (Cr2/1) on Scrapie Pathogenesis in Mice.

Authors:  Sarah J Kane; Eric Swanson; Elizabeth O Gordon; Savannah Rocha; Heather R Bender; Luke R Donius; Adriano Aguzzi; Jonathan P Hannan; Mark D Zabel
Journal:  mSphere       Date:  2017-11-22       Impact factor: 4.389

8.  Negative selection of human germinal center B cells by prolonged BCR cross-linking.

Authors:  L Galibert; N Burdin; C Barthélémy; G Meffre; I Durand; E Garcia; P Garrone; F Rousset; J Banchereau; Y J Liu
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

Review 9.  Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.

Authors:  Jack Mellors; Tom Tipton; Stephanie Longet; Miles Carroll
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

Review 10.  Complement Receptor 1: disease associations and therapeutic implications.

Authors:  Rohan Khera; Nibhriti Das
Journal:  Mol Immunol       Date:  2008-11-11       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.